Literature DB >> 28132521

Direct Intracranial Injection of AAVrh8 Encoding Monkey β-N-Acetylhexosaminidase Causes Neurotoxicity in the Primate Brain.

Diane Golebiowski1,2, Imramsjah M J van der Bom3,4, Churl-Su Kwon5, Andrew D Miller6, Keiko Petrosky6, Allison M Bradbury7,8, Stacy Maitland1,2, Anna Luisa Kühn3,4, Nina Bishop9, Elizabeth Curran6, Nilsa Silva6, Dwijit GuhaSarkar1,2, Susan V Westmoreland6, Douglas R Martin7,8, Matthew J Gounis3,4, Wael F Asaad10,11,12, Miguel Sena-Esteves1,2.   

Abstract

GM2 gangliosidoses, including Tay-Sachs disease and Sandhoff disease, are lysosomal storage disorders caused by deficiencies in β-N-acetylhexosaminidase (Hex). Patients are afflicted primarily with progressive central nervous system (CNS) dysfunction. Studies in mice, cats, and sheep have indicated safety and widespread distribution of Hex in the CNS after intracranial vector infusion of AAVrh8 vectors encoding species-specific Hex α- or β-subunits at a 1:1 ratio. Here, a safety study was conducted in cynomolgus macaques (cm), modeling previous animal studies, with bilateral infusion in the thalamus as well as in left lateral ventricle of AAVrh8 vectors encoding cm Hex α- and β-subunits. Three doses (3.2 × 1012 vg [n = 3]; 3.2 × 1011 vg [n = 2]; or 1.1 × 1011 vg [n = 2]) were tested, with controls infused with vehicle (n = 1) or transgene empty AAVrh8 vector at the highest dose (n = 2). Most monkeys receiving AAVrh8-cmHexα/β developed dyskinesias, ataxia, and loss of dexterity, with higher dose animals eventually becoming apathetic. Time to onset of symptoms was dose dependent, with the highest-dose cohort producing symptoms within a month of infusion. One monkey in the lowest-dose cohort was behaviorally asymptomatic but had magnetic resonance imaging abnormalities in the thalami. Histopathology was similar in all monkeys injected with AAVrh8-cmHexα/β, showing severe white and gray matter necrosis along the injection track, reactive vasculature, and the presence of neurons with granular eosinophilic material. Lesions were minimal to absent in both control cohorts. Despite cellular loss, a dramatic increase in Hex activity was measured in the thalamus, and none of the animals presented with antibody titers against Hex. The high overexpression of Hex protein is likely to blame for this negative outcome, and this study demonstrates the variations in safety profiles of AAVrh8-Hexα/β intracranial injection among different species, despite encoding for self-proteins.

Entities:  

Keywords:  AAV; Tay-Sachs disease; adeno-associated virus; gene therapy; hexosaminidase; intracranial delivery

Mesh:

Substances:

Year:  2017        PMID: 28132521      PMCID: PMC5488349          DOI: 10.1089/hum.2016.109

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  64 in total

1.  Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS.

Authors:  M A Zanta-Boussif; S Charrier; A Brice-Ouzet; S Martin; P Opolon; A J Thrasher; T J Hope; A Galy
Journal:  Gene Ther       Date:  2009-03-05       Impact factor: 5.250

2.  Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses.

Authors:  Roberto Calcedo; Luk H Vandenberghe; Guangping Gao; Jianping Lin; James M Wilson
Journal:  J Infect Dis       Date:  2009-02-01       Impact factor: 5.226

3.  Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease.

Authors:  James C Dodge; Jennifer Clarke; Antonius Song; Jie Bu; Wendy Yang; Tatyana V Taksir; Denise Griffiths; Michael A Zhao; Edward H Schuchman; Seng H Cheng; Catherine R O'Riordan; Lamya S Shihabuddin; Marco A Passini; Gregory R Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

Review 4.  Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.

Authors:  R J Desnick; E H Schuchman
Journal:  Annu Rev Genomics Hum Genet       Date:  2012       Impact factor: 8.929

5.  Tay-Sachs disease in Jacob sheep.

Authors:  Paola A Torres; Bai Jin Zeng; Brian F Porter; Joseph Alroy; Fred Horak; Joan Horak; Edwin H Kolodny
Journal:  Mol Genet Metab       Date:  2010-08-14       Impact factor: 4.797

6.  Inefficiency in GM2 ganglioside elimination by human lysosomal beta-hexosaminidase beta-subunit gene transfer to fibroblastic cell line derived from Sandhoff disease model mice.

Authors:  Tomohiro Itakura; Aya Kuroki; Yasuhiro Ishibashi; Daisuke Tsuji; Eri Kawashita; Yukari Higashine; Hitoshi Sakuraba; Shoji Yamanaka; Kohji Itoh
Journal:  Biol Pharm Bull       Date:  2006-08       Impact factor: 2.233

7.  Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice.

Authors:  J E Guidotti; A Mignon; G Haase; C Caillaud; N McDonell; A Kahn; L Poenaru
Journal:  Hum Mol Genet       Date:  1999-05       Impact factor: 6.150

8.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.

Authors:  Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-31       Impact factor: 11.454

9.  Mechanisms of distribution of mouse beta-galactosidase in the adult GM1-gangliosidosis brain.

Authors:  M L D Broekman; L A Tierney; C Benn; P Chawla; J H Cha; M Sena-Esteves
Journal:  Gene Ther       Date:  2008-09-25       Impact factor: 5.250

10.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

View more
  26 in total

1.  Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.

Authors:  Hannah G Lahey; Chelsea J Webber; Diane Golebiowski; Cassandra M Izzo; Erin Horn; Toloo Taghian; Paola Rodriguez; Ana Rita Batista; Lauren E Ellis; Misako Hwang; Douglas R Martin; Heather Gray-Edwards; Miguel Sena-Esteves
Journal:  Mol Ther       Date:  2020-06-19       Impact factor: 11.454

2.  Recombinant Adeno-Associated Virus Gene Therapy in Light of Luxturna (and Zolgensma and Glybera): Where Are We, and How Did We Get Here?

Authors:  Allison M Keeler; Terence R Flotte
Journal:  Annu Rev Virol       Date:  2019-07-05       Impact factor: 10.431

3.  Brain endothelial specific gene therapy improves experimental Sandhoff disease.

Authors:  Godwin Dogbevia; Hanna Grasshoff; Alaa Othman; Anke Penno; Markus Schwaninger
Journal:  J Cereb Blood Flow Metab       Date:  2019-07-29       Impact factor: 6.200

Review 4.  Lysosomal Leukodystrophies Lysosomal Storage Diseases Associated With White Matter Abnormalities.

Authors:  Gustavo H B Maegawa
Journal:  J Child Neurol       Date:  2019-02-13       Impact factor: 1.987

5.  AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset.

Authors:  David Goertsen; Nicholas C Flytzanis; Nick Goeden; Miguel R Chuapoco; Alexander Cummins; Yijing Chen; Yingying Fan; Qiangge Zhang; Jitendra Sharma; Yangyang Duan; Liping Wang; Guoping Feng; Yu Chen; Nancy Y Ip; James Pickel; Viviana Gradinaru
Journal:  Nat Neurosci       Date:  2021-12-09       Impact factor: 24.884

Review 6.  Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary.

Authors:  Jill A Morris; Chris H Boshoff; Nina F Schor; Ling M Wong; Guangping Gao; Beverly L Davidson
Journal:  Mol Ther       Date:  2021-09-20       Impact factor: 11.454

Review 7.  A Historical Review of Brain Drug Delivery.

Authors:  William M Pardridge
Journal:  Pharmaceutics       Date:  2022-06-16       Impact factor: 6.525

8.  [Progressive psychomotor regression for 2.5 years in a boy aged 5 years].

Authors:  Mao-Qiang Tian; Xiao-Xi Chen; Lei Li; Chang-Hui Lang; Juan Li; Jing Chen; Xiao-Hua Yu; Xiao-Mei Shu
Journal:  Zhongguo Dang Dai Er Ke Za Zhi       Date:  2022-06-15

9.  Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease.

Authors:  Karolina M Stepien; Su Han Lum; J Edmond Wraith; Christian J Hendriksz; Heather J Church; David Priestman; Frances M Platt; Simon Jones; Ana Jovanovic; Robert Wynn
Journal:  JIMD Rep       Date:  2017-12-07

10.  Krabbe disease successfully treated via monotherapy of intrathecal gene therapy.

Authors:  Allison M Bradbury; Jessica H Bagel; Duc Nguyen; Erik A Lykken; Jill Pesayco Salvador; Xuntian Jiang; Gary P Swain; Charles A Assenmacher; Ian J Hendricks; Keiko Miyadera; Rebecka S Hess; Arielle Ostrager; Patricia ODonnell; Mark S Sands; Daniel S Ory; G Diane Shelton; Ernesto R Bongarzone; Steven J Gray; Charles H Vite
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.